1)Bosman FT, Carneiro F, Hruban RH, et al (eds):WHO Classification of Tumors of the Digestive System (World Health Organization Classification of Tumors). Lyon, IARC Press, 2010
2)日本神経内分泌腫瘍研究会:膵・消化管神経内分泌腫瘍(NET)診療ガイドライン,第1版.2013
3)Boukhman MP, Karam JM, Shaver J, et al:Localization of insulinomas. Arch Surg 134:818-822, 1999
4)Steinmuller T, Kianmanesh R, Falconi M, et al;Frascati Consensus Conference participants:Consensus guidelines for the management of patients with liver metastases from digestive (neuro) endocrine tumors:foregut, midgut, hindgut, and unknown primary. Neuroendocrinology 87:47-62, 2008
5)Rindi G, Luinetti O, Cornaggia M, et al:Three subtypes of gastric argyrophil carcinoid and the gastric neuroendocrine carcinoma:a clinicopathologic study. Gastroenterology 104:994-1006, 1993
6)Ito T, Sasano H, Tanaka M, et al:Epidemiological study of gastroenteropancreatic neuroendocrine tumors in Japan. J Gastroenterol 45:234-243, 2010
7)大沼 忍,内藤 剛,羽根田祥,他:直腸神経内分泌腫瘍に対する治療方針.癌と化療40:2077-2079, 2013
8)DeLellis RA, Lloyd RV, Heitz PU, et al (eds):WHO Classification of Tumours, Pathology and Genetics. Tumours of Endocrine Organs. Lyon, IARC Press, 2004
9)Fjallslog ML, Granberg DP, Welin SL, et al:Treatment with cisplatin and etoposide in patients with neuroendocrine tumors. Cancer 92:1101-1107, 2001
10)青木 豪,大塚英郎,海野倫明:膵内分泌腫瘍(P-NET)外科の新たな潮流:P-NETの治療方針.日内分泌・甲状腺外会誌30:271-274, 2013